Litcius/Paper detail

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

Yongjun Wang, Yongjun Wang, Shuya Li, Yuesong Pan, Hao Li, Mark W Parsons, Bruce Campbell, Lee H. Schwamm, Marc Fisher, Fengyuan Che, Hongguo Dai, Deyang Li, Runhui Li, Junhai Wang, Yilong Wang, Yilong Wang, Xingquan Zhao, Zixiao Li, Huaguang Zheng, Yunyun Xiong, Meng Xia, Runhui Li, Dong Wang, Yongjun Wang, Yongjun Wang, Shengli Chen, Dan Deng, Hong Zhang, Junhai Wang, Dawei Chen, Hongwei Zhang, Yiping Wu, Hong Liu, Guozhi Lu, Liandong Zhao, Runxiu Zhu, Ying Liu, Fei Yi, Jianhua Gao, Hongguo Dai, Junfang Hao, Fengyuan Che, Xueli Cai, Zhihui Duan, Yu Hong, Tongguo Wei, Yufeng Tang, Zhaolong Peng, Baochao Zhang, Yan Song, Xiaofei Chen, Yunling Liu, Jing Liu, Deyang Li, Weili Zhao, Xiue Wei, Qian Xue, Xuewen Liu, Yi Yang, Chuansheng Zhao, Jun Chen, Yi Sui, Guizhi Sheng, Yun Zhang, Junyan Liu, Lianhuan Zhang, Weiwei Wang, Zhiyong Guo, Hao Li, Renping Hu, Guofang Chen, Zhigang Liang, Junbin Chen, L. Xia, Zhihua Long

2023The Lancet294 citationsDOI

Topics & Concepts

MedicineTenecteplaseModified Rankin ScaleThrombolysisStroke (engine)Clinical endpointFibrinolytic agentRandomized controlled trialClinical trialPopulationInternal medicineTissue plasminogen activatorMyocardial infarctionIschemic strokeIschemiaMechanical engineeringEngineeringEnvironmental healthAcute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage ResearchS100 Proteins and Annexins
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial | Litcius